Categories
Blood Cancer

Emina Hubanić – The Role of JAK3 in Leukemia [Video]

Title: The Role of JAK3 in LeukemiaStudent: Emina HubanićCategory: MastersInstitution: Faculty of Life Sciences, University of Vienna, Austria—- Research Abstract: The JAK/STAT pathway has a role in the hematopoietic system and its components were found to be mutated in blood cancers. In my Master’s thesis project, using mouse and cell models, I have worked on investigating gain of function mutations of JAK3 and their ability to cause leukaemia. —- The three-minute thesis (3MT) competition challenges research students to communicate the significance of their projects to a non-specialist audience in just three minutes. Students from Bosnia/Herzegovina and diaspora showcase their research work and talent.————————————The foundation aims to transform Bosnia & Herzegovina into a prosperous nation that can respond to the challenges of the 21st century. It does this by empowering the youth through non-formal education, technology access, and the development of world-class leadership skills.————————————Learn more about us! WEBSITE: bhfuturesfoundation.org————————————© Copyright 2021 Bosnia & Herzegovina Futures Foundation – All rights reserved.

Categories
Blood Cancer

Hana Šahinbegović – Identification of novel targets for the improvement of multiple myeloma therapy [Video]

Title: Understanding of current and identification of novel targets for the improvement of multiple myeloma therapyStudent: Hana ŠahinbegovićCategory: Ph.D.Institution: Faculty of Science, University of Ostrava—- Research Abstract: Multiple myeloma (MM), an aggressive type of blood cancer, remains fatal despite recent advances in treatment. We’re trying to understand how this treatment works, why it fails, how can it be improved and whether there are better treatment options in general for this type of cancer. —- The three-minute thesis (3MT) competition challenges research students to communicate the significance of their projects to a non-specialist audience in just three minutes. Students from Bosnia/Herzegovina and diaspora showcase their research work and talent.————————————The foundation aims to transform Bosnia & Herzegovina into a prosperous nation that can respond to the challenges of the 21st century. It does this by empowering the youth through non-formal education, technology access, and the development of world-class leadership skills.————————————Learn more about us! WEBSITE: bhfuturesfoundation.org————————————© Copyright 2021 Bosnia & Herzegovina Futures Foundation – All rights reserved.

Categories
Breast Cancer

Women’s Health | Dr. Hanadi BuAli | Breast Cancer Screening | Self Exam | Ascension Wisconsin [Video]

https://ascension.org/WisconsinWomensBy getting to know you and your health history, we can recommend the breast screening that’s right for you.

Categories
Breast Cancer

Women’s Health | Dr. Hanadi BuAli | Breast Cancer Screening | Risk Factors | Ascension Wisconsin [Video]

https://ascension.org/WisconsinWomensBy getting to know you and your health history, we can recommend the breast screening that’s right for you.

Categories
Prostate Cancer

Common prostate cancer medications may be less safe than previously thought [Video]

Common prostate cancer medications may be less safe than previously thought Disclaimer :Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research.Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. https://tinyurl.com/TodaySciencology#Science #Technology #Invention #ScienceDailyMen taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients who were only receiving hormone therapy, Michigan Medicine researchers found. Patients taking abiraterone had 1.77 times the risk of being admitted to the emergency room or the hospital due to diabetes, hypertension or heart disease compared to those who were only on hormone therapy. Those receiving enzalutamide were at 1.22 times the risk of these issues. Compared to patients not receiving abiraterone, those taking abiraterone were also more likely to need an outpatient visit with their physician related to at least one of these health conditions. That was not the case if the man was taking enzalutamide. Abiraterone and enzalutamide were both found to be relatively safe in clinical trials, but concerns that the population of patients who participated in the trials was different than those in real-life settings prompted the researchers to take another look at the effects of the drugs. For instance, this research exclusively analyzed patients with Medicare health insurance, and the majority of men studied were significantly older than those in the drugs’ clinical trials. “Patients enrolled in clinical trials tend to be highly selected and often times do not reflect the patient population in day-to-day practice,” said Lillian Y. Lai, M.D., M.S., a National Institutes of Health T32 Urologic Oncology Research Fellow at Michigan Medicine and the first author of the study. “Trial participants also undergo stringent safety evaluations that some of our patients do not have access to. By studying adverse events in real-life settings, we can better understand the risks of these life-prolonging cancer treatments and help clinicians and patients make informed decisions regarding treatment.” Since metabolic and cardiovascular conditions tend to be under the purview of primary care providers, Lai and her fellow authors recommend team-based care that involves PCPs for patients with advanced prostate cancer as a way to manage these higher risks. “With continued expansion of the indications for abiraterone and enzalutamide to earlier stages of the disease, increasing numbers of men will be receiving these therapies for longer periods of time,” Lai said. “This will potentially amplify the scope of men affected and increase the magnitude of the risks of adverse events, making careful attention to management of these issues crucial.” Other authors include Mary K. Oerline, M.S.; Megan E.V. Caram, M.D., M.S.; Phoebe A. Tsao, M.D.; Samuel R. Kaufman, M.A.; Brent K. Hollenbeck, M.D., M.S.; and Vahakn B. Shahinian, M.D., M.S. make a difference: sponsored opportunity Story Source: Materials provided by Michigan Medicine – University of Michigan. Original written by Mary Clare Fischer. Note: Content may be edited for style and length. Journal Reference: Lillian Y Lai, Mary K Oerline, Megan E V Caram, Phoebe A Tsao, Samuel R Kaufman, Brent K Hollenbeck, Vahakn B Shahinian. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. JNCI: Journal of the National Cancer Institute, 2022; DOI: 10.1093/jnci/djac081 Cite This Page: Michigan Medicine – University of Michigan. “Common prostate cancer medications may be less safe than previously thought.” ScienceDaily. ScienceDaily, 25 May 2022. . Michigan Medicine – University of Michigan. (2022, May 25). Common prostate cancer medications may be less safe than previously thought. ScienceDaily. Retrieved May 25, 2022 from https://ift.tt/0sb746x Michigan Medicine – University of Michigan. “Common prostate cancer medications may be less safe than previously thought.” ScienceDaily. https://ift.tt/0sb746x (accessed May 25, 2022).

Categories
Breast Cancer

Women’s Health | Dr. Hanadi BuAli | Breast Cancer Screening | Family History | Ascension Wisconsin [Video]

https://ascension.org/WisconsinWomensBy getting to know you and your health history, we can recommend the breast screening that’s right for you.

Categories
Breast Cancer

Women’s Health | Dr. Hanadi BuAli | Breast Cancer Screening | Surgical Options | Ascension Wisconsin [Video]

https://ascension.org/WisconsinWomensBy getting to know you and your health history, we can recommend the breast screening that’s right for you.

Categories
Breast Cancer

Women’s Health | Dr. Hanadi BuAli | Breast Cancer Screening | Cosmetic | Ascension Wisconsin [Video]

https://ascension.org/WisconsinWomensBy getting to know you and your health history, we can recommend the breast screening that’s right for you.

Categories
Breast Cancer

Women’s Health | Dr. Hanadi BuAli | Breast Cancer Screening | 90 | Ascension Wisconsin [Video]

https://ascension.org/WisconsinWomensBy getting to know you and your health history, we can recommend the breast screening that’s right for you.

Categories
Brain Cancer

Novel approach could lead to treatment of devastating brain tumors [Video]

Novel approach could lead to treatment of devastating brain tumors Disclaimer :Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research.Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. https://tinyurl.com/TodaySciencology#Science #Technology #Invention #ScienceDailyFindings from a seven-year research project suggests that there could be a new approach to treating one of the most common and devasting forms of brain cancer in adults — Glioblastoma Multiforme (GBM). In a peer-reviewed study published by BMC Cancer, scientists from the University of Surrey show that a short chain of amino acids (the HTL-001 peptide) is effective at targeting and inhibiting the function of a family of genes responsible for the growth of GBM — Hox genes. The study was conducted in cell and animal models. The HTL-001 peptide used in the study has undergone safety testing and is suitable for patient trials. These trials are now being considered in GBM and other cancers. Hardev Pandha, project lead and Professor of Medical Oncology at the University of Surrey, said: “People who suffer from Glioblastoma Multiforme have a five per cent survival rate over a five-year period — a figure that has not improved in decades. While we are still early in the process, our seven-year project offers a glimmer of hope for finding a solution to Hox gene dysregulation, which is associated with the growth of GBM and other cancers, and which has proven to be elusive as a target for so many years.” Ironically, Hox genes are responsible for the healthy growth of brain tissue but are ordinarily silenced at birth after vigorous activity in the growing embryo. However, if they are inappropriately ‘switched on’ again, their activity can lead to the progression of cancer. Hox gene dysregulation has long been recognised in GBM. The project was carried out in collaboration with the universities of Surrey, Leeds and Texas, and HOX Therapeutics, a University of Surrey start-up company based on the University’s Surrey Research Park. Professor Susan Short, co-author of the study from the University of Leeds, said: “We desperately need new treatment avenues for these aggressive brain tumours. Targeting developmental genes like the HOX genes that are abnormally switched on in the tumour cells could be a novel and effective way to stop glioblastomas growing and becoming life-threatening.” James Culverwell, CEO of HOX Therapeutics, said: “HOX Therapeutics is excited to be associated with this project and we hope that with our continuing support, this research will eventually lead to novel and effective treatments for both brain and other cancers where HOX gene over-expression is a clear therapeutic target.” make a difference: sponsored opportunity Story Source: Materials provided by University of Surrey. Note: Content may be edited for style and length. Journal Reference: Einthavy Arunachalam, William Rogers, Guy R. Simpson, Carla Möller-Levet, Gemma Bolton, Mohammed Ismael, Christopher Smith, Karl Keegen, Izhar Bagwan, Tim Brend, Susan C. Short, Bangxing Hong, Yoshihiro Otani, Balveen Kaur, Nicola Annels, Richard Morgan, Hardev Pandha. HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme. BMC Cancer, 2022; 22 (1) DOI: 10.1186/s12885-022-09466-8 Cite This Page: University of Surrey. “Novel approach could lead to treatment of devastating brain tumors.” ScienceDaily. ScienceDaily, 9 May 2022. . University of Surrey. (2022, May 9). Novel approach could lead to treatment of devastating brain tumors. ScienceDaily. Retrieved May 9, 2022 from https://ift.tt/hzRD9EH University of Surrey. “Novel approach could lead to treatment of devastating brain tumors.” ScienceDaily. https://ift.tt/hzRD9EH (accessed May 9, 2022).

Categories
Pancreatic Cancer

Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene… [Video]

Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene…